In the present work, special emphasize has been given on cancer. Cancer, an unwanted growth of cells, is supposed to be the most deadly diseases because of its high prevalence and late detection. During the past quarter century exceptional progress in fundamental cancer biology has not translated into comparable advances in the clinic. Also, the failure or rather low success rate of cancer chemotherapy is in the cytotoxicity exhibited by these drugs. Hence, inspite of several anticancer molecules with diverse targets, there is still a room for selective therapies which will have specificity in their action leaving host cells unaffected. Tuberculosis is still a major cause of death across the globe. The great challenge lies in the emergence of MDR-TB and XDR-TB associated with immuno-deficient diseases like AIDS. In such scenario, the search for novel mechanism, novel target and new molecules are always desired which can be used as front line drug to tackle the battle against this deadliest disease.
